targeting acute, life threatening and chronic inflammatory diseases with new and selective inhibitors of the C5a/C5aR signaling pathway of the immune system's complement cascade.
To learn more about our ongoing phase 3 trial for treating ulcerative pyoderma gangrenosum, please visit clinicaltrials.gov
InflaRx is developing highly specific therapeutics targeting the C5a/C5aR signaling axis of the complement system. InflaRx has made breakthrough discoveries in the area of selective anti-C5a antibody generation and C5a receptor (C5aR) inhibitors.
InflaRx focuses on diseases with high unmet medical need. Vilobelimab, the company's first-in-class anti-human C5a monoclonal antibody is currently being developed in several chronic inflammatory diseases, as well as oncology and for the treatment of critically ill COVID-19 patients.
Gohibic (vilobelimab) - FDA has issued an emergency use authorization (EUA) to treat certain critically ill COVID-19 patients.
The latest information on InflaRx share price with interactive charts, comparative analysis, historic figures and latest trade price is available here.
Jena, Germany, December 20, 2024 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneeri...
Jena, Germany, November 15, 2024 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneeri...
Jena, Germany, November 8, 2024 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneerin...
Jena, Germany, October 31, 2024 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneerin...
Jena, Germany, September 25, 2024 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneer...
Jena, Germany, September 3, 2024 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneeri...
Jena, Germany, August 27, 2024 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering...
Jena, Germany, August 8, 2024 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering ...
Jena, Germany, August 1, 2024 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering ...
Jena, Germany, July 30, 2024 – InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering a...
